ArticlePloS one2026
Activation and DNA methylation of PANoptosis in polycystic ovary syndrome.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolycystic ovarian syndrome (PCOS) is a reproductive endocrine disorder involving various pathophysiological factors and is currently incurable. This study aimed to explore the potential role of pan-apoptosis in PCOS.
methodsDifferentially expressed genes (DEGs) between PCOS and healthy controls were identified in GSE155489 and GSE10946, and enrichment analysis was performed. The activation of PANoptosis in PCOS was evaluated, PANoptosis-related DEGs were screened, and the receiver operating characteristic (ROC) curve was plotted. The methylation modification of PANoptosis-related DEGs were assessed from differentially methylated probes in GSE80468 dataset. Protein expression was detected using Western blot, and DNA methylation levels were measured using PCR in PCOS patients and healthy controls.
resultsPANoptosis was significantly activated in PCOS. The intersection DEGs in GSE155489 and GSE10946 datasets significantly participated in signaling pathways such as Cell adhesion molecules, B cell receptor signaling pathway, and Rap1 signaling pathway. TNFSF10, IL-18, and CASP2 were differentially expressed in PCOS and may be subject to methylation modification, with the ROC curve suggesting they have diagnostic roles in PCOS. Experimental detection confirmed that TNFSF10 is hypomethylated and highly expressed in PCOS, while CASP2 is hypermethylated and lowly expressed in PCOS.
conclusionThrough comprehensive analysis of gene expression and DNA methylation data, this study revealed the correlation between PCOS and PANoptosis, providing new insights into the molecular basis of PCOS and offering potential biomarkers for the development of future diagnostic and therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.